Hamartoma Whole Blood
About: Whole blood from donors with confirmed hamartoma. Useful for TSC1/TSC2 gene variant research and mTOR inhibitor therapy studies.
<h2>Hamartoma Whole Blood for Research</h2>
Hamartomas are benign, disorganized tissue growths that can arise in the lung, hypothalamus, and other organs, sometimes linked to genetic syndromes such as tuberous sclerosis. Sanguine collects fresh whole blood from IRB-consented donors with a clinically confirmed hamartoma diagnosis for oncology and genetic research.
<h3>Product Features</h3>
<ul><li>Fresh whole blood from clinically diagnosed hamartoma donors</li><li>Custom anticoagulants and collection tubes available</li><li>Same-day collection and shipment</li><li>Research Use Only (RUO)</li></ul>
<h3>De-identified Donor Data</h3>
<ul><li>Physician-confirmed diagnosis, including tumor location and associated syndrome where available</li><li>Demographics: age, sex assigned at birth, ethnicity</li><li>Relevant medical and family history</li></ul>
<h3>Applications</h3>
<ul><li>TSC1/TSC2 and related gene variant research</li><li>Benign tumor growth pathway studies</li><li>Gene expression and transcriptomic analysis</li><li>mTOR inhibitor therapy response research</li></ul>
<h3>Compliance and Quality</h3>
<ul><li>IRB-approved protocols and electronic informed consent</li><li>HIPAA-compliant donor data handling</li></ul>
<h3>Ordering and Customization</h3>
Hamartoma whole blood is available in standard and custom volumes. Email <a href=”mailto:learnmore@sanguinebio.com”>learnmore@sanguinebio.com</a> for international orders or documentation requirements.
Whole Blood
Frequently Asked Questions
1 Answer
Collected and shipped same-day – local pickup may be available. For more information, request a quote or contact: LearnMore@sanguinebio.com
1 Answer
YES – The same-day program processes and ships samples on the day of collection, ensuring delivery well within 48 hours for the designated service areas.
Ask a Question
Need a custom Whole Blood cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.